MYELOFIBROSIS

This study tests a new device that filters excess iron from the blood in people with myelodysplastic syndrome (MDS) or myelofibrosis who cannot take standard iron-removing medications. Participants will undergo three short dialysis-like sessions over one week. The goal is to see …

This study tests an experimental drug called RVU120 in adults with intermediate or high-risk myelofibrosis, a type of bone marrow cancer. Participants will receive RVU120 alone or together with the standard drug ruxolitinib. The main goal is to see if the treatment can shrink the…

This study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in adults with blood cancers who are at high risk of rejecting a stem cell transplant. Participants receive the drug before standard transplant preparation to reduce DSA levels enough to al…

This study tests a new drug called elritercept (KER-050) in about 135 adults with myelofibrosis, a rare bone marrow cancer. The drug is given alone or with the standard medicine ruxolitinib. The main goals are to check safety and see if it helps with anemia and other symptoms. Th…

This early-stage study tests an experimental drug called JNJ-88549968 in people with certain blood cancers (myelofibrosis or essential thrombocythemia) that have a specific CALR gene mutation. The drug is a bispecific antibody designed to redirect the body's immune T-cells to att…

This early-phase study tests whether Nelfinavir, a drug originally used for HIV, can improve anemia in people with myelofibrosis, a rare bone marrow cancer. The goal is to restore iron delivery to the bone marrow and reduce fibrosis. About 10 adults with low hemoglobin will take …

This study compares two approaches to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body after a stem cell transplant. About 400 adults with blood cancers like leukemia or lymphoma will receive either thymoglobulin or a co…

This program provides early access to the investigational drug selinexor for people with multiple myeloma, lymphoma, sarcoma, or other cancers who have exhausted all approved treatments and cannot join a clinical trial. Patients must get approval from their doctor and local healt…

This study tests whether giving high doses of ruxolitinib and busulfan before a stem cell transplant can reduce spleen size and improve transplant outcomes in people with myelofibrosis. About 30 adults aged 18 to 75 with an enlarged spleen and a matched donor will take part. The …

This study tests a drug called selinexor in people with myelofibrosis who have low platelet counts and have not yet taken JAK inhibitors. The main goal is to see if the drug can shrink the spleen by at least 35% after 24 weeks. About 58 adults will take selinexor alone, and resea…

This early-phase study tests a new drug (imetelstat) added to the standard treatment (ruxolitinib) for people with myelofibrosis, a rare bone marrow cancer. The goal is to find the best dose and see if the combination safely reduces symptoms like fatigue and spleen discomfort. Ab…

This study uses a cord blood transplant after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. About 200 participants will receive the transplant to see if it improves survival one year later. The approach aims to replace diseased bone …

This study tests a two-step, lower-intensity approach using radiation and chemotherapy before a stem cell transplant for people with various blood cancers or disorders. The goal is to see if this gentler preparation reduces the risk of death from the transplant itself. About 63 p…

This study tests whether adding ulixertinib to the standard drug ruxolitinib is safe and works for people with myelofibrosis, a type of bone marrow cancer. About 37 adults who are already on a stable dose of ruxolitinib will join. Researchers will try different doses of ulixertin…

This study tests an experimental pill called nuvisertib for people with myelofibrosis, a type of bone marrow cancer. It is for those with intermediate or high-risk disease who have not responded well to standard JAK inhibitor therapy. The main goals are to check safety and see if…

This study tests whether adding navtemadlin to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis who didn't get enough benefit from ruxolitinib. About 600 adults with high- or intermediate-risk myelofibrosis will take part. The goal i…

This early-phase study tests whether the drug momelotinib is safe for people with myelofibrosis (a rare bone marrow cancer) who are getting a stem cell transplant. About 28 adults with advanced disease will receive the drug during and after transplant to find the best dose and ch…

This study is testing an experimental drug called DISC-0974 in about 150 adults with myelofibrosis or myelodysplastic syndrome (MDS) who also have anemia. The goal is to see if the drug can help patients produce enough red blood cells so they no longer need regular blood transfus…

This study is for people with certain blood cancers (like essential thrombocythemia or myelofibrosis) who have already been taking the drug bomedemstat and are doing well on it. The goal is to collect more information on the drug's long-term safety and how well it continues to wo…

This study tests new drug combinations to prevent graft-versus-host disease (GVHD) in people with blood cancers who receive stem cells from an unrelated donor. About 358 participants will get either the standard GVHD prevention drugs or a new mix, and researchers will compare whi…

This study tests whether a combination of two experimental drugs (TQ05105 and TQB3617) can safely reduce spleen size and improve symptoms in adults with intermediate- or high-risk myelofibrosis, a type of bone marrow cancer. About 92 participants will receive the treatment to fin…

This study tests a new daily pill, LP-118, in up to 100 people with blood cancers that have come back or not responded to treatment. The main goal is to find the safest dose and see how the drug works in the body. Early results will also hint at whether it can shrink tumors or sl…

This early-stage trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV), a common and dangerous infection after transplant. About 46 people with various blood cancers or disorders will take part. The g…

This study tests a vaccine (CMV-MVA Triplex) given to stem cell donors to help prevent CMV infection in patients receiving a stem cell transplant. The vaccine boosts the donor's immunity against CMV, which is then passed to the patient through the transplant. About 216 donor-reci…

This study looks at whether N-Acetylcysteine (N-AC), a common supplement, can reduce symptoms like fatigue and pain in adults with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. About 27 participants with essential thrombocythemia, polycythemia vera, or myelo…

This study tests whether a curcumin supplement can reduce inflammation and improve symptoms in people with certain blood disorders, including CCUS, low-risk MDS, and MPNs. The trial will enroll 30 participants who will receive either curcumin or a placebo for 12 months. Researche…

This study is a registry that will follow about 200 people in Germany who have myelofibrosis (a rare bone marrow disorder) and anemia. It does not test a new treatment but instead collects information on which therapies patients receive, how their blood counts and spleen size res…

This study looks at how the drug TQ05105 behaves in people with mild or moderate liver impairment compared to healthy volunteers. It involves 24 adults aged 18-75 who take a single dose of the drug. The goal is to measure drug levels in the blood and check for side effects, helpi…

This study is testing whether an artificial intelligence (AI) tool can help match people with advanced cancer to the right clinical trials. Researchers will enroll up to 50,000 participants to see if the AI improves trial enrollment rates and patient outcomes. The goal is to make…

This study looks at whether a special type of PET/MRI scan (18F-FAPI) can accurately diagnose and track myelofibrosis, a serious bone marrow disorder. Researchers will compare the scan results with the standard bone marrow biopsy in 57 participants. The goal is to see if this non…

This study tests a telehealth program to help older adults (60+) with blood cancers like leukemia talk with their doctors about their care wishes. It aims to reduce anxiety and improve completion of advance directives. About 207 patients and their caregivers will participate remo…

This study is not testing a new treatment. Instead, it will follow about 617 adults diagnosed with myelofibrosis (a rare bone marrow cancer) across Europe. Researchers will collect information from medical records to understand how the disease progresses and how patients respond …

This study follows 5,000 adults with myeloproliferative neoplasms (MPNs) — rare blood cancers — to understand how symptoms change and how the disease progresses over years. Participants share their health records, insurance data, and regular surveys about how they feel. No new tr…

This study looks at how changes in the ASXL1 gene affect myelofibrosis, a rare bone marrow disorder. Researchers will study 50 adults to find different patterns of these gene changes and see how they relate to patient outcomes. The goal is to better understand the disease and imp…